AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Wednesday that its subsidiary NV Hemispherx Biopharma Europe has received formal notification from the European Commission approving the company’s Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer.
The company noted that medications designated as Orphan products by the European Medicines Agency (EMA), once commercially approved in the European Union (EU), receive benefits including up to 10 years of protection from market competition from similar medicines with similar active components and indication-for-use that are not shown to be clinically superior.
AIM ImmunoTech announced earlier this month that the Committee for Orphan Medicinal Products of the EMA had recommended that Ampligen receive the designation for pancreatic cancer. The company has now received the official approval of that designation.
READ: AIM ImmunoTech announces expansion of its pancreatic cancer program to include new patients in the Netherlands
“Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide with over 458,000 worldwide cases of pancreatic cancer in 2018 alone,” said Dr Casper van Eijck, the lead investigator for the expanded access program for Ampligen at Erasmus Medical Center in the Netherlands, in a statement.
“Despite advancements in the detection and management of pancreatic cancer, the 5-year survival rate is only 5-10%. Due to the positive and statistically significant survival results, versus historical controls, that we observed when using Ampligen in patients with locally advanced/metastatic pancreatic cancer–after systemic chemotherapy–we believe that Ampligen has the potential to be a meaningful extension of the standard of care for advanced pancreatic cancer.”
Dr van Eijck added: “We are currently writing the manuscript describing the results of our study and are planning to investigate Ampligen further in the follow-up pancreatic cancer Phase 2/3 clinical trial and in a Phase 1 trial in combination with checkpoint inhibitors at Erasmus Medical Center.”
AIM ImmunoTech CEO Thomas K. Equels noted that orphan medicinal product designation in the EU and in the US is a critical milestone in the company's ongoing efforts to develop Ampligen as a treatment for pancreatic cancer.
“Pancreatic cancer is one of the deadliest cancers because, far too often, it is not diagnosed until Stage IV, when the disease is so far along that there are limited therapeutic options,” Equals said. “We at AIM hope that Ampligen can one day help add precious time to the lives of many people suffering from pancreatic cancer.”
Orphan medicinal product designations promote the clinical development of drugs that target rare life-threatening conditions, and which are expected to provide significant therapeutic advantage over existing treatments.
READ: AIM ImmunoTech completes and closes ATM facility, says current capital expected to meet needs for clinical trials
Sponsors who obtain EMA orphan designation “benefit from protocol assistance, a type of scientific advice specific for designated orphan medicines, and market exclusivity once the medicine is on the market,” according to the EMA. Fee reductions are also available depending on circumstances.
The EMA designation follows a similar approval from the US Food and Drug Administration (FDA), which also awarded AIM ImmunoTech with orphan drug designation status for Ampligen as a treatment for pancreatic cancer.
The FDA orphan designation followed the company’s September 2020 announcement of statistically significant positive pancreatic cancer survival benefit in the Ampligen arm as compared to a historical control cohort seen in a multi-year Early Access Program conducted at Erasmus University Medical Center.
The use of Ampligen following the current standard of care for pancreatic cancer (FOLFIRINOX) yielded an overall survival of 19 months, 7.9 months greater than FOLFIRINOX treatment alone, AIM ImmunoTech said.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham